From: Cardiovascular secondary prevention in high-risk patients: a randomized controlled trial sub-study
Intervention | Control | p-value | |
---|---|---|---|
LDL-C ≥ 2.5/1.8a baseline, n | 87 | 78 | |
LDL-C baseline, median (25th–75th percentile) | 2.9 (2.6–3.5) | 2.9 (2.7–3.7) | 0.74 |
LDL-C 12 months, median (25th–75th percentile) | 2.2 (1.8–3.0)*** | 3.0 (2.4–3.4)** | <0.001 |
SBP ≥ 140 baseline, n | 89 | 95 | |
SBP baseline, median (25th–75th percentile) | 150 (142–160) | 150 (140–160) | 0.97 |
SBP 12 months, median (25th–75th percentile) | 140 (129–155)*** | 145 (130–158)*** | 0.26 |
DBP ≥ 90 baseline, n | 25 | 26 | |
DBP baseline, median (25th–75th percentile) | 90 (90–95) | 90 (90–96) | 0.71 |
DBP 12 months, median (25th–75th percentile) | 80 (75–86)*** | 80 (75–91)*** | 0.48 |